# Ablynx, a Sanofi company clinical trials: 25 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 25 trials with Ablynx, a Sanofi company as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Ablynx, a Sanofi company: 25 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/ablynx-a-sanofi-company

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 25
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 25, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| March 19, 2018 | NCT03468829 | Efficacy and Safety of ALX-0171 in Adult Hematopoietic Stem Cell Transplant (HSCT) Recipients Who Present With Respiratory Syncytial Virus... | Ablynx, a Sanofi company | Phase 2 | Withdrawn | Respiratory Syncytial Virus Lower Respiratory Tract Infection | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03468829) |
| February 1, 2018 | NCT03418571 | Evaluation of ALX-0171 in Japanese Children Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection | Ablynx, a Sanofi company | Phase 2 | Terminated | Respiratory Syncytial Virus Lower Respiratory Tract Infection | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03418571) |
| June 1, 2017 | NCT03172208 | Caplacizumab Single and Multiple Dose Study in Healthy Japanese and White Subjects. | Ablynx, a Sanofi company | Phase 1 | Completed | Healthy Volunteers | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03172208) |
| December 1, 2016 | NCT02979431 | Dose Ranging Study of ALX-0171 in Infants Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection | Ablynx, a Sanofi company | Phase 2 | Completed | Respiratory Syncytial Virus Lower Respiratory Tract Infection | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02979431) |
| September 17, 2015 | NCT02553317 | Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura | Ablynx, a Sanofi company | Phase 3 | Completed | Acquired Thrombotic Thrombocytopenic Purpura | 145 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02553317) |
| August 10, 2015 | NCT02518620 | An Open-Label Extension Study Assessing the Long-Term Efficacy and Safety of ALX-0061 in Subjects With Rheumatoid Arthritis | Ablynx, a Sanofi company | Phase 2 | Completed | Rheumatoid Arthritis | 406 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02518620) |
| May 8, 2015 | NCT02437890 | A Phase II Study to Evaluate Safety and Efficacy of ALX-0061 in Subjects With Systemic Lupus Erythematosus | Ablynx, a Sanofi company | Phase 2 | Completed | Lupus Erythematosus, Systemic | 312 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02437890) |
| December 5, 2014 | NCT02309359 | A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis | Ablynx, a Sanofi company | Phase 2 | Completed | Rheumatoid Arthritis | 345 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02309359) |
| December 5, 2014 | NCT02309320 | A Multicentre Study in Otherwise Healthy Infants and Toddlers Hospitalised For and Diagnosed With RSV Lower Respiratory Tract Infection to... | Ablynx, a Sanofi company | Phase 1/2 | Completed | Respiratory Syncytial Virus Infection | 53 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02309320) |
| November 11, 2014 | NCT02287922 | A Phase IIb Study for ALX-0061 Monotherapy in Subjects With Rheumatoid Arthritis | Ablynx, a Sanofi company | Phase 2 | Completed | Rheumatoid Arthritis | 251 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02287922) |
| July 15, 2014 | NCT02189733 | Bioequivalence of Liquid and Reconstituted Lyophilized Subcutaneous Formulations of Caplacizumab. | Ablynx, a Sanofi company | Phase 1 | Completed | Healthy Volunteers | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02189733) |
| April 1, 2014 | NCT02101073 | ALX-0061 Phase I Bioavailability Study in Healthy Volunteers | Ablynx, a Sanofi company | Phase 1 | Completed | Rheumatoid Arthritis | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02101073) |
| July 29, 2013 | NCT01909843 | ALX-0171 Safety Study in Adults With Hyperresponsive Airways | Ablynx, a Sanofi company | Phase 1 | Completed | Respiratory Syncytial Virus Infection | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01909843) |
| June 12, 2013 | NCT01875926 | ALX-0171 Phase I Pharmacokinetic Study in Healthy Male Volunteers | Ablynx, a Sanofi company | Phase 1 | Completed | Healthy, RSV Infection | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01875926) |
| December 2, 2011 | NCT01483911 | ALX-0171 Phase I Study, Evaluating Single Ascending Dose and Multiple Dose in Healthy Male Volunteers | Ablynx, a Sanofi company | Phase 1 | Completed | RSV Infection | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01483911) |
| July 25, 2011 | NCT01401764 | Study Comparing The Tolerability Of Three Excipient Formulations Administered Subcutaneously To Healthy Subjects | Ablynx, a Sanofi company | Phase 1 | Completed | Healthy | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01401764) |
| June 16, 2011 | NCT01374503 | First in Man Study of ALX-0651, a Nanobody Inhibiting CXCR4 | Ablynx, a Sanofi company | Phase 1 | Terminated | Healthy Volunteers | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01374503) |
| January 27, 2011 | NCT01284569 | Study to Assess Safety and Efficacy of Anti-Interleukin 6-receptor (IL6R) Nanobody in Rheumatoid Arthritis (RA) Patients | Ablynx, a Sanofi company | Phase 1/2 | Completed | Rheumatoid Arthritis | 65 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01284569) |
| January 26, 2011 | NCT01284036 | A Single Dose Study Of The Safety And Investigational Product Level Measurement In Healthy Subjects | Ablynx, a Sanofi company | Phase 1 | Completed | Healthy | 63 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01284036) |
| June 28, 2010 | NCT01151423 | Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic... | Ablynx, a Sanofi company | Phase 2 | Completed | Acquired Thrombotic Thrombocytopenic Purpura | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01151423) |
| February 5, 2010 | NCT01063803 | Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis | Ablynx, a Sanofi company | Phase 2 | Completed | Rheumatoid Arthritis | 266 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01063803) |
| November 24, 2009 | NCT01020383 | Comparative Study of ALX-0081 Versus GPIIb/IIIa Inhibitor in High Risk Percutaneous Coronary Intervention (PCI) Patients | Ablynx, a Sanofi company | Phase 2 | Completed | Unstable Angina, Non ST Segment Elevation Myocardial Infarction (NSTEMI), Stable Angina (Associated With High Risk PCI) | 364 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01020383) |
| November 3, 2009 | NCT01007175 | Study Evaluating Multiple Ascending Doses Of ATN-103 In Japanese Subjects With Rheumatoid Arthritis | Ablynx, a Sanofi company | Phase 1/2 | Completed | Rheumatoid Arthritis | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01007175) |
| August 14, 2009 | NCT00959036 | Study Evaluating Multiple Doses Of ATN-103 In Subjects With Active Rheumatoid Arthritis | Ablynx, a Sanofi company | Phase 1/2 | Completed | Active Rheumatoid Arthritis | 252 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00959036) |
| June 9, 2009 | NCT00916110 | Study Of Single Dose Of ATN-103 Administered To Healthy Japanese Male Subjects | Ablynx, a Sanofi company | Phase 1 | Completed | Healthy | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00916110) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 10 |
| Phase 1/2 | 4 |
| Phase 2 | 10 |
| Phase 3 | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 22 |
| Terminated | 2 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Arthritis, Rheumatoid | 7 |
| Respiratory Syncytial Virus Infections | 4 |
| Purpura, Thrombotic Thrombocytopenic | 2 |
| Angina, Unstable | 1 |
| Non-ST Elevated Myocardial Infarction | 1 |
| Angina, Stable | 1 |
| Lupus Erythematosus, Systemic | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Seafood restaurants in the United States](https://specstream.ai/data/businesses/seafood-restaurants/united-states)
- [Gardening services in the United States](https://specstream.ai/data/businesses/gardening-services/united-states)
- [Advertising agencies in the United States](https://specstream.ai/data/businesses/advertising-agencies/united-states)
- [Medical supply stores in the United States](https://specstream.ai/data/businesses/medical-supply-stores/united-states)
- [Chicken restaurants in the United States](https://specstream.ai/data/businesses/chicken-restaurants/united-states)
- [Retaining wall suppliers in the United States](https://specstream.ai/data/businesses/retaining-wall-suppliers/united-states)
